O
TRIL

OrbiMed’s Trillium Therapeutics Inc. TRIL Stock Holding History

OrbiMed’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,700
Closed -$18K – 181
2021
Q1 		$18K Buy
+1,700
New +$21K ﹤0.01% 158

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

OrbiMed's TRIL Position: Q3 2021 in Review

OrbiMed sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 3,322,300 shares — an estimated $32.2M sold.

OrbiMed first reported a position in TRIL in Q1 2020 and held it in 6 quarters. The position peaked at $43.5M in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • OrbiMed reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • OrbiMed sold 3,322,300 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $32.2M.
  • OrbiMed first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 6 quarters.
  • OrbiMed's Trillium Therapeutics Inc. position peaked at $43.5M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.